Immunization against αIIb β3 and αv β3 in Glanzmann thrombasthenia patients carrying the French Gypsy mutation
- PMID: 33090654
- DOI: 10.1111/jth.15117
Immunization against αIIb β3 and αv β3 in Glanzmann thrombasthenia patients carrying the French Gypsy mutation
Abstract
Essentials The c.1544+1G>A mutation was identified in Gypsy Glanzmann thrombasthenia (GT) patients. Gypsy GT patients express normal αv β3 carrying HPA-1b epitopes. To demonstrate HPA-1a alloimmunization by modified antigen capture assays. Gypsy GT patients could develop anti-HPA-1a alloantibodies against β3 and αv β3 . ABSTRACT: Background Glanzmann thrombasthenia (GT) is a rare bleeding disorder caused by the absence or the dysfunction of the platelet αIIb β3 integrin. A founder mutation in the ITGA2B gene was previously identified in French Gypsy patients. Interestingly, this mutation was strongly linked to the human platelet antigen-1b (HPA-1b). The HPA-1bb Gypsy patients are at risk of isoimmunization against αIIb β3 , as this complex is not expressed at their platelet surface. Tentatively, they would, however, not have an increased risk of developing anti-HPA-1a alloantibodies by exposure of αIIb β3 on platelets from random platelet transfusions. However, the β3 chain can also associate with the αv subunit expressed at the platelet surface. Because Gypsy GT patients express normal αv β3 carrying HPA-1b epitopes, these patients might develop anti-HPA-1a alloantibodies reacting with αv β3 and/or β3 . Objectives/Patients/Methods To demonstrate this hypothesis, sera from HPA-1bb (n = 5) and HPA-1ab (n = 1) Gypsy GT patients were investigated by modified antigen capture assay using platelets or stable transfected cells. Furthermore, stable transfected cells expressing either αIIb β3 or αv β3 together with soluble monomeric chimeric β3 (as absorbent) were used to differentiate anti-β3 and anti-αv β3 reactivity. Results Only HPA-1bb patients developed alloantibodies reacting with HPA-1a cells. Further analysis showed that HPA-1bb patients developed anti-HPA-1a alloantibodies reacting with β3 and/or αv β3 . Conclusion In this study, we found that HPA-1bb patients who failed to express αIIb β3 on the platelet surface can develop alloantibodies against HPA-1a reacting with β3 as well as αv β3 . This is of particular importance as anti-HPA-1a alloantibodies might cause fetal neonatal alloimmune thrombocytopenia and/or platelet transfusion refractoriness.
Keywords: GP IIb/IIIa; endothelial cells; inherited/acquired platelet disorders; integrins; transfusion medicine.
© 2020 International Society on Thrombosis and Haemostasis.
Similar articles
-
Analysis of platelet membrane glycoprotein polymorphisms in Glanzmann thrombasthenia showed the French gypsy mutation in the alphaIIb gene to be strongly linked to the HPA-1b polymorphism in beta3.J Thromb Haemost. 2003 Mar;1(3):573-5. doi: 10.1046/j.1538-7836.2003.00107.x. J Thromb Haemost. 2003. PMID: 12871468
-
First description of an IgM monoclonal antibody causing αIIb β3 integrin activation and acquired Glanzmann thrombasthenia associated with macrothrombocytopenia.J Thromb Haemost. 2019 May;17(5):795-802. doi: 10.1111/jth.14424. Epub 2019 Apr 19. J Thromb Haemost. 2019. PMID: 30868743
-
Current Anti-HPA-1a Standard Antibodies React with the β3 Integrin Subunit but not with αIIbβ3 and αvβ3 Complexes.Thromb Haemost. 2019 Nov;119(11):1807-1815. doi: 10.1055/s-0039-1696716. Epub 2019 Oct 6. Thromb Haemost. 2019. PMID: 31587244 Free PMC article.
-
Anti-αIIb β3 immunization in Glanzmann thrombasthenia: review of literature and treatment recommendations.Br J Haematol. 2018 Apr;181(2):173-182. doi: 10.1111/bjh.15087. Epub 2018 Apr 2. Br J Haematol. 2018. PMID: 29611179 Review.
-
Glanzmann thrombasthenia: genetic basis and clinical correlates.Haematologica. 2020 Apr;105(4):888-894. doi: 10.3324/haematol.2018.214239. Epub 2020 Mar 5. Haematologica. 2020. PMID: 32139434 Free PMC article. Review.
Cited by
-
Profiling the Genetic and Molecular Characteristics of Glanzmann Thrombasthenia: Can It Guide Current and Future Therapies?J Blood Med. 2021 Jul 8;12:581-599. doi: 10.2147/JBM.S273053. eCollection 2021. J Blood Med. 2021. PMID: 34267570 Free PMC article. Review.
References
REFERENCES
-
- Fiore M, Nurden AT, Nurden P, Seligsohn U. Clinical utility gene card for: Glanzmann thrombasthenia. Eur J Hum Genet. 2012;20:10.
-
- Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis. 2006;1:10.
-
- Grainger JD, Thachil J, Will AM. How we treat the platelet glycoprotein defects; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults. Br J Haematol. 2018;182:621-632.
-
- Bolton-Maggs PH, Chalmers EA, Collins PW, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol. 2006;135:603-633.
-
- Kirchmaier CM, Pillitteri D. Diagnosis and management of inherited platelet disorders. Transfus Med Hemother. 2010;37:237-246.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous